You are here » Home » Companies » Company Overview » Syngene International Ltd

Syngene International Ltd.

BSE: 539268 Sector: Health care
NSE: SYNGENE ISIN Code: INE398R01022
BSE LIVE 09:50 | 23 Nov 527.95 6.00
(1.15%)
OPEN

524.90

HIGH

537.80

LOW

520.00

NSE 09:35 | 23 Nov 536.00 13.40
(2.56%)
OPEN

526.95

HIGH

539.00

LOW

521.25

OPEN 524.90
PREVIOUS CLOSE 521.95
VOLUME 2048172
52-Week high 663.30
52-Week low 430.00
P/E 36.19
Mkt Cap.(Rs cr) 10,559
Buy Price 527.95
Buy Qty 23.00
Sell Price 528.75
Sell Qty 100.00
OPEN 524.90
CLOSE 521.95
VOLUME 2048172
52-Week high 663.30
52-Week low 430.00
P/E 36.19
Mkt Cap.(Rs cr) 10,559
Buy Price 527.95
Buy Qty 23.00
Sell Price 528.75
Sell Qty 100.00

Syngene International Ltd. (SYNGENE) - Company History

Syngene International Limited is an internationally reputed contract research and manufacturing organisation with multidisciplinary skills in chemistry and biology services. The company was promoted by Biocon and Kiran Mazumdar Shaw a promoter of Biocon Limited. The company was formed with objectives of providing contract research service to overseas customer in the field of synthetic chemistry molecular biology and custom synthesis.The company was incorporated at Bangalore in the year 1993. During the year 1994-1995 the company pioneered in CRO services for both Chemistry and Biology. During the year 2001-2002 the company acquired a new facility inclusive of a cGMP pilot plant. In March 30 2002 the company's 99.9% equity share was transferred to Biocon and the company became a subsidiary of Biocon Ltd. During the year 2003-2004 the company introduced Process Research and Optimization Services. In October 21 2004 the company commissioned a new research facility at Boammasandra Bangalore. In February 15 2006 the company commissioned new facility at Biocon Park. In August 30 2006 the company received approval of additional facility to set up as SEZ unit from Cochin Special Economic Zone. During the year 2006-2007 Bristol- Myers Squibb had entered into a long term agreement with the company to set up an exclusive research facility to house more than 400 scientists. During the year the company had ventured into other area of Biology viz Genetic Engineering Protein Chemistry and assay development. The company had developed extensive expertise in the creation of customized stable cell lines expressing proteins / receptors of intersest. During the year 2007-2008 the company entered a long term service agreement with BMS. During the year 2008-2009 the company created an alliance partnership with DuPont Crop Protection.